Dupixent® Linked to
Cutaneous T-Cell Lymphoma (CTCL)
If you used Dupixent (dupilumab) for eczema, asthma, or other conditions and were diagnosed with T-cell lymphoma or CTCL, you may be entitled to significant compensation from Sanofi and Regeneron.
Quick Eligibility Check
What is Dupixent?
Dupixent (dupilumab) is an injectable biologic medication manufactured by Sanofi and Regeneron Pharmaceuticals. It is approved to treat moderate-to-severe atopic dermatitis (eczema), asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and other inflammatory conditions.
Marketed as a breakthrough therapy that targets specific immune pathways, Dupixent has been used by hundreds of thousands of patients. However, recent lawsuits allege the manufacturers failed to warn about a serious cancer risk.
Dupixent Linked to T-Cell Lymphoma (CTCL)
Lawsuits allege that Dupixent’s immune-modulating mechanism may cause, unmask, or accelerate the development of cutaneous T-cell lymphoma (CTCL) and other T-cell lymphomas.
Cutaneous T-Cell Lymphoma (CTCL)
A rare, aggressive form of non-Hodgkin lymphoma that affects the skin and can spread. Symptoms include persistent rashes, plaques, tumors, and itching. Often misdiagnosed as worsening eczema.
Strong Scientific & Legal Evidence
- Post-marketing reports of lymphoma in Dupixent users
- Alleged failure to warn about cancer risk
- Drug may suppress immune surveillance of early lymphoma
Manufacturers’ Alleged Failure
Sanofi and Regeneron are accused of knowing or should have known about the lymphoma risk but failed to adequately warn patients and physicians — prioritizing sales over safety.
Current Dupixent Mass Tort Status
As of May 2026 – and growing rapidly
IN RE: Dupixent (Dupilumab) Products Liability Litigation – MDL 3180
Motion to centralize filed February 2026. JPML hearing held May 28, 2026. Sanofi & Regeneron agree cases should be consolidated. This emerging pharmaceutical mass tort is one of the fastest-moving of 2026.
Why victims are pursuing compensation:
- Failure to warn about lymphoma risk
- Inadequate post-market surveillance
- Misleading safety information
Do You Qualify for the Dupixent Lawsuit?
Most qualifying victims meet these criteria:
For eczema, asthma, nasal polyps, or other approved conditions (any duration)
Cutaneous T-Cell Lymphoma (CTCL), mycosis fungoides, Sézary syndrome, or other T-cell lymphoma
*Not everyone who used Dupixent will qualify. A free review is required to confirm eligibility.
Get Your FREE Case Review
Takes less than 60 seconds. Our team will review your information and connect you with top mass tort attorneys.
Frequently Asked Questions
How much compensation can I expect?
Projected settlement ranges in similar cancer-related pharmaceutical cases are $50,000 to over $1,000,000 depending on diagnosis stage, treatment intensity, and long-term impact. Final values will be determined as the litigation progresses.
How long do I have to file?
Statutes of limitations vary by state and are often based on when the cancer was diagnosed and when the connection to Dupixent was discovered. The sooner you contact us, the better we can protect your rights.
What if I don’t remember exact dates of use?
Our team works with medical record retrieval services at no cost to you. We can obtain pharmacy and treatment records to establish eligibility.
Do I have to go to court?
Most mass tort cases resolve through settlement. You will likely not need to appear in court personally.
Don’t Wait — Dupixent CTCL Cases Are Moving Fast
This litigation is in its earliest and most critical stage. Secure your place before the MDL is fully established and bellwether trials begin.
PPC Squared Mass Torts • Franklin, TN • We connect qualified victims with the nation’s leading mass tort law firms